Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 8,151 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Terminated Phase 2 Interventional Results available

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

NCT00240162
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

NCT01126970
View directory record Official record
Conditions
Obesity
Interventions
Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Not applicable Interventional

DRIHNC - Dehydration Reduction in Head & Neck Cancer

NCT03799380
View directory record Official record
Conditions
Dehydration, Head & Neck Cancer, Esophageal Cancer
Interventions
Gatorade G2, Standard of care nutritional support
Dietary Supplement
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

NCT00473720
View directory record Official record
Conditions
Advanced Cancers
Interventions
Satraplatin, Abraxane
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 29, 2026, 1:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

NCT00660088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Ketasyn
Other
Lead sponsor
Cerecin
Industry
Eligibility
55 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 29, 2026, 1:37 AM EDT
Recruiting Phase 1 Interventional

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

NCT07006688
View directory record Official record
Conditions
IDH1-Mutated Malignancies
Interventions
Ivosidenib Oral Tablet
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 4 Interventional Results available

(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist

NCT03381261
View directory record Official record
Conditions
Migraine
Interventions
Botulinum toxin type A
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

NCT00833261
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, intensity-modulated radiation therapy, Nab-Paclitaxel
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Cleveland, Ohio • Dallas, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01303796
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sapacitabine, Decitabine
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
70 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Antibacterial Mouthwash on Muscle Function in Healthy Young Men and Women

NCT04095442
View directory record Official record
Conditions
Quadriceps Muscle
Interventions
Cepacol, Tom's Natural Mouthwash
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00019461
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboxyamidotriazole, chemotherapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers

NCT00752843
View directory record Official record
Conditions
Healthy Subjects
Interventions
mifepristone + fluvastatin
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 3 Interventional

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

NCT00092508
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
OPC-6535, Asacol®
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
26
States / cities
Huntsville, Alabama • Los Angeles, California • Hollywood, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2007 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time

NCT02267850
View directory record Official record
Conditions
Malocclusion
Interventions
Fixed Orthodontic Appliance Treatment, OrthoPulse™, Non-Functional OrthoPulse™
Other · Device
Lead sponsor
Biolux Research Holdings, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Suwanee, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 29, 2026, 1:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

NCT05237960
View directory record Official record
Conditions
Erythroplakia, Oral Leukoplakia
Interventions
Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride, Placebo Administration
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • San Diego, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects

NCT01813461
View directory record Official record
Conditions
Pharmacokinetics of 14C-labeled Isavuconazole, Healthy Subjects
Interventions
14C-labeled prodrug isavuconazonium sulfate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

Study to Assess VB-201 in Patients With Psoriasis

NCT01001468
View directory record Official record
Conditions
Active Plaque Psoriasis
Interventions
VB-201, Placebo
Drug · Other
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Boston, Massachusetts • Haverhill (Boston), Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

NCT00283816
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 29, 2026, 1:37 AM EDT
Not listed Not applicable Interventional

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

NCT06344416
View directory record Official record
Conditions
Any Solid Oral Medication
Interventions
Use of ReX to dispense and monitor solid oral medication therapy.
Device
Lead sponsor
Dosentrx Ltd.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Minneapolis, Minnesota • Austin, Texas • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Not applicable Interventional

Oral vs Intravenous Acetominophen for Postoperative Pain in Minimally Invasive Gynecologic Surgery

NCT03391284
View directory record Official record
Conditions
Post-operative Pain
Interventions
acetominophen, Acetaminophen
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 29, 2026, 1:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Web-based Education on Oral Cancer for Primary Care Physicians in Ohio

NCT01424358
View directory record Official record
Conditions
Oral Cancer
Interventions
Web-based Educational Intervention
Other
Lead sponsor
Creighton University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 29, 2026, 1:37 AM EDT
Completed No phase listed Observational

A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus

NCT00521378
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 29, 2026, 1:37 AM EDT